Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6052703 | Journal of Cranio-Maxillofacial Surgery | 2014 | 7 Pages |
Abstract
The cell lines used in this study responded poorly to cetuximab and panitumumab. Better anti-EGFR treatment efficacy was related to lower EGFR expression in head and neck cancer cell lines. These findings might influence the selection of patients to receive cetuximab and panitumumab treatment for head and neck cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
Stefan Hartmann, Axel Seher, Roman C. Brands, Christian Linz, Grit Lessner, Hartmut Böhm, Alexander C. Kübler, Urs D.A. Müller-Richter,